Metastasis Molecular Mechanism/Biomarkers for Individual Therapy
Rui-hua Xu’s Laboratory

Prof. Rui-hua Xu’s Laboratory belongs to the Department of Medical Oncology, Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China. Prof. Xu’s Lab is interested in:

1) Finding novel molecular mechanisms of gastrointestinal cancer metastasis;

2) Identifying potential diagnostic and prognostic biomarkers to guide individualized therapy for cancer patients;

3) Developing new strategies to overcome drug resistance of cancer cells;

4) Conducting clinical trials for developing optimal treatments for cancer patients.

Research Projects
1. Role of miR-214 in the regulation of colorectal cancer liver metastasis and its underlying mechanisms.

2. Defining new molecular subtypes and developing individualized therapy for advanced colorectal and gastric cancer.

3. Role of AMPK in the regulationof Kras and PI3K signaling pathway in colorectal cancer.

4. KH903 Clinical trial: a novelanti-angiogenic antibody in the treatment of cancer patients.

Selected peer-reviewed publications

(1)      Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q,Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J,Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y,Yang Q, Zou J, Xu RH#  ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep14;326(10):916-925.

(2)      Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, FlorianLordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, SangCheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh,Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-HuaXu#. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric orgastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141.

(3)       Xu RH*#, WeiW, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L,Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z,Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, LiO, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.

(4)       Xu RH*#, MuroK, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH,Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, ParkYS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI(leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab,as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre,open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.

(5)      Li J, Qin S, Xu R*, Yau TC, Ma B,Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T,Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind,placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.

(6)      Luo H, Xu G, Li C, He L, Luo L, Wang Z,Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J,Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, XuRH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.

(7)      Satoh T, Xu RH*, Chung HC, Sun GP,Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, YehKH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib pluspaclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized,phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.

(8)      Manish A. Shah, Rui-hua Xu*,Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, FanXia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric orGastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017;35: 2558-2567.

(9)      Yan-Xing Chen, Zi-Xian Wang, Ying Jin, QiZhao, Ze-Xian Liu, Zhi-Xiang Zuo, Huai-Qiang Ju, Chengxu Cui, Jun Yao, YanqiaoZhang, Mengxia Li, Jifeng Feng, Lin Tian, Xiao-Jun Xia, Hui Feng, Sheng Yao,Feng-Hua Wang, Yu-Hong Li, Feng Wang, Rui-Hua Xu#. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell. 2023 May8;41(5):919-932.e5. doi: 10.1016/j.ccell.2023.03.016. Epub 2023 Apr 13.

(10)  Wang ZX, Cui C, Yao J, Zhang Y, Li M, FengJ, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L,Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, RenW, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, HuangC, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, MaD, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, LiJ, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, WangT, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#,Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.

(11)   Wang F,Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.

(12)  Wang F, Liu DB, Zhao Q, Chen G, Liu XM,Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and XuRH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.

Contact Information
Rui-hua Xu, Ph.D.
Principle Investigator
Professor of Department of Medical Oncology
President of Sun Yat-sen University Cancer Center

651 Dong Feng East Road,
Guangzhou 510060, PR China
Office: +86-20-87343333
Fax: +86-20-87343295

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.